Factory Price Clopidogrel Hydrogen Sulfate Powder CAS 135046-48-9

• Powder: Yes
• Customized: Customized
• Certification: GMP, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Model NO.: HRK-Clopidogrel Hydrogen Sulfate
• Product Name: Clopidogrel Hydrogen Sulfate Powder
• Appearance: White Powder
• Test: HPLC
• Mf: C13h19no4s
• CAS: 135046-48-9
• MW: 419.03
• Active Ingredient: Clopidogrel Hydrogen Sulfate
• Sample: Clopidogrel Hydrogen Sulfate Avaliable
• Certificate: GMP ISO USP Bp
• Assay: 90% Min
• Grade Standard: Feed Grade, Food Grade, Medicine Grade
• Application: Vertinary Raw Materials
• Type of Product: Auxiliaries and Other Medicinal Chemicals
• Storage: Cool Dry Place
• Shelf Life: 2 Years Proper Storage
• Transport Package: 1kg Per Foil Bag, 10 Bags Per Carton. 25 Kg Per Dr
• Specification: 99% min Tetramisole HCl
• Trademark: Henrikang
• Origin: Shaanxi China
• Production Capacity: 500000kg/Year

Product Description

Factory Price Clopidogrel Hydrogen Sulfate Powder CAS 135046-48-9

Product Name	Factory Price Clopidogrel Hydrogen Sulfate Powder CAS 135046-48-9
CAS	135046-48-9
Appearance	White Powder
Molecular formula	C13H19NO4S
Molecular Weight	419.03
Assay	98%
Shelf Life	24 months when properly stored
Storage	Keep in a cool, dry, dark location

 

What is Clopidogrel hydrogen sulfate? Clopidogrel is an effective antiplatelet agent useful for the treatment of ischemic cerebrovascular, cardiac, and peripheral arterial disease.

Fuction of Clopidogrel hydrogen sulfate

Clopidogrel is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease,
peripheral vascular disease, and cerebrovascular disease. The drug works by irreversibly inhibiting a receptor called
P2Y12, an adenosine diphosphate (ADP) chemoreceptor on platelet cell membranes. Adverse effects include
hemorrhage, severe neutropenia, and thrombotic thrombocytopenic purpura (TTP).

Application of Clopidogrel hydrogen sulfate

Clopidogrel is used in the prevention of atherothrombotic events in the following patients:
1. Patients with myocardial infarction (from a few days to less than 35 days), patients with ischemic stroke (from 7
days to less than 6 months), or patients with confirmed peripheral arterial disease.
2, patients with acute coronary syndrome
Non-ST-segment elevation acute coronary syndrome (including unstable angina or non-Q-wave myocardial infarction)
, including patients with stent placement after percutaneous coronary intervention, in combination with aspirin.
 For patients with ST-segment elevation acute coronary syndrome, combined with aspirin, can be combined for use
in thrombolytic therapy.